Glycolysis metabolites and risk of atrial fibrillation and heart failure in the PREDIMED trial

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Becerra-Tomás, Nerea
  • dc.contributor.author Fitó Colomer, Montserrat
  • dc.contributor.author Salas Salvadó, Jordi
  • dc.date.accessioned 2022-03-30T07:18:45Z
  • dc.date.available 2022-03-30T07:18:45Z
  • dc.date.issued 2021
  • dc.description.abstract The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR for 1 SD increase: 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.
  • dc.description.sponsorship This research was funded by The National Institutes of Health (R01HL118264), the Spanish Ministry of Health (Instituto de Salud Carlos III), and the Ministerio de Economía y Competitividad-Fondo Europeo de Desarrollo Regional (Projects CNIC-06/2007, RTIC G03/140, CIBER 06/03, PI06-1326, PI07-0954, PI11/02505, SAF2016-80532, SAF2009-12304 and AGL2010-22319-C03-03), and by the Generalitat Valenciana (PROMETEO 17/2017, ACOMP2010-181, AP111/10, AP-042/11, ACOM2011/145, ACOMP/2012/190, ACOMP/2013/159 and ACOMP/213/165), and CIBER Obesidad y Nutrición, Madrid, Spain, Fondo de Investigación Sanitaria, Madrid, Spain. THEMATIC NETWORK “PREDIMED”, RD 06/0045, coordinated by MAM-G, funded by ISCIII 2006-2013. N. Becerra-Tomás, a postdoctoral fellowship (Juan de la Cierva Formación, FJC2018-036016-I); P. Hernández-Alonso, a postdoctoral fellowship (Juan de la Cierva Formación, FJCI-2017-32205); M. Guasch-Ferré, American Diabetes Association grant #1-18-PMF-029; E. Ros, grants for research through his institution from the California Walnut Commission (CWC); J. Salas-Salvadó (senior author of this work), partially supported by ICREA under the ICREA Academia programme, grants/research support from the American Pistachio Growers and International Nut and Dried Fruit Foundation through his Institution.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Becerra-Tomás N, Ruiz-Canela M, Hernández-Alonso P, Bulló M, Li J, Guasch-Ferré M et al. Glycolysis metabolites and risk of atrial fibrillation and heart failure in the PREDIMED trial. Metabolites. 2021 May 11;11(5):306. DOI: 10.3390/metabo11050306
  • dc.identifier.doi http://dx.doi.org/10.3390/metabo11050306
  • dc.identifier.issn 2218-1989
  • dc.identifier.uri http://hdl.handle.net/10230/52800
  • dc.language.iso eng
  • dc.publisher MDPI
  • dc.relation.ispartof Metabolites. 2021 May 11;11(5):306
  • dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2016-80532
  • dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/SAF2009-12304
  • dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/AGL2010-22319-C03-03
  • dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by/4.0/
  • dc.subject.keyword PREDIMED study
  • dc.subject.keyword Atrial fibrillation
  • dc.subject.keyword Glycolysis
  • dc.subject.keyword Heart failure
  • dc.title Glycolysis metabolites and risk of atrial fibrillation and heart failure in the PREDIMED trial
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)